Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

really promising data of pembro-GVD in 39 relapsed Hodgkins patients, 79% had either primary refractory or early relapse. 95% of the patients made it to AutoSCT, all of whom are disease free at median f/u of 13.5 months.

Read the full article here

Related Articles